197 related articles for article (PubMed ID: 23077450)
1. Improved survival after introduction of chemotherapy for malignant pleural mesothelioma in Slovenia: Population-based survey of 444 patients.
Kovac V; Zwitter M; Zagar T
Radiol Oncol; 2012 Jun; 46(2):136-44. PubMed ID: 23077450
[TBL] [Abstract][Full Text] [Related]
2. Durvalumab with first-line chemotherapy in previously untreated malignant pleural mesothelioma (DREAM): a multicentre, single-arm, phase 2 trial with a safety run-in.
Nowak AK; Lesterhuis WJ; Kok PS; Brown C; Hughes BG; Karikios DJ; John T; Kao SC; Leslie C; Cook AM; Pavlakis N; Briscoe K; O'Byrne KJ; Karapetis CS; Lam WS; Langford A; Yip S; Stockler MR
Lancet Oncol; 2020 Sep; 21(9):1213-1223. PubMed ID: 32888453
[TBL] [Abstract][Full Text] [Related]
3. Bevacizumab for newly diagnosed pleural mesothelioma in the Mesothelioma Avastin Cisplatin Pemetrexed Study (MAPS): a randomised, controlled, open-label, phase 3 trial.
Zalcman G; Mazieres J; Margery J; Greillier L; Audigier-Valette C; Moro-Sibilot D; Molinier O; Corre R; Monnet I; Gounant V; Rivière F; Janicot H; Gervais R; Locher C; Milleron B; Tran Q; Lebitasy MP; Morin F; Creveuil C; Parienti JJ; Scherpereel A;
Lancet; 2016 Apr; 387(10026):1405-1414. PubMed ID: 26719230
[TBL] [Abstract][Full Text] [Related]
4. Patterns of failure following surgical resection for malignant pleural mesothelioma.
Jänne PA; Baldini EH
Thorac Surg Clin; 2004 Nov; 14(4):567-73. PubMed ID: 15559064
[TBL] [Abstract][Full Text] [Related]
5. Incidence and survival of malignant pleural mesothelioma in norway: a population-based study of 1686 cases.
Helland Å; Solberg S; Brustugun OT
J Thorac Oncol; 2012 Dec; 7(12):1858-1861. PubMed ID: 23154557
[TBL] [Abstract][Full Text] [Related]
6. Pemetrexed disodium for the treatment of malignant pleural mesothelioma: a systematic review and economic evaluation.
Dundar Y; Bagust A; Dickson R; Dodd S; Green J; Haycox A; Hill R; McLeod C; Walley T
Health Technol Assess; 2007 Jan; 11(1):1-90. PubMed ID: 17181984
[TBL] [Abstract][Full Text] [Related]
7. Efficacy of second-line treatment and prognostic factors in patients with advanced malignant peritoneal mesothelioma: a retrospective study.
Kitadai R; Shimoi T; Sudo K; Noguchi E; Nagata Y; Sawada R; Takashima A; Boku N; Yonemori K
BMC Cancer; 2021 Mar; 21(1):294. PubMed ID: 33743636
[TBL] [Abstract][Full Text] [Related]
8. Safety and activity of microRNA-loaded minicells in patients with recurrent malignant pleural mesothelioma: a first-in-man, phase 1, open-label, dose-escalation study.
van Zandwijk N; Pavlakis N; Kao SC; Linton A; Boyer MJ; Clarke S; Huynh Y; Chrzanowska A; Fulham MJ; Bailey DL; Cooper WA; Kritharides L; Ridley L; Pattison ST; MacDiarmid J; Brahmbhatt H; Reid G
Lancet Oncol; 2017 Oct; 18(10):1386-1396. PubMed ID: 28870611
[TBL] [Abstract][Full Text] [Related]
9. Efficacy, Safety, and Cost-Minimization Analysis of Continuous Infusion of Low-Dose Gemcitabine Plus Cisplatin in Patients With Unresectable Malignant Pleural Mesothelioma.
Arrieta O; Muñoz-Montaño W; Muñiz-Hernández S; Campos S; Catalán R; Soto-Molina H; Guzmán Vázquez S; Díaz-Álvarez O; Martínez-Pacheco V; Turcott JG; Ramos-Ramírez M; Cabrera-Miranda L; Barrón F; Cardona AF
Front Oncol; 2021; 11():641975. PubMed ID: 33959504
[TBL] [Abstract][Full Text] [Related]
10. Tumour Treating Fields in combination with pemetrexed and cisplatin or carboplatin as first-line treatment for unresectable malignant pleural mesothelioma (STELLAR): a multicentre, single-arm phase 2 trial.
Ceresoli GL; Aerts JG; Dziadziuszko R; Ramlau R; Cedres S; van Meerbeeck JP; Mencoboni M; Planchard D; Chella A; Crinò L; Krzakowski M; Rüssel J; Maconi A; Gianoncelli L; Grosso F
Lancet Oncol; 2019 Dec; 20(12):1702-1709. PubMed ID: 31628016
[TBL] [Abstract][Full Text] [Related]
11. Malignant mesothelioma incidence by nation-wide cancer registry: a population-based study.
Tomasson K; Gudmundsson G; Briem H; Rafnsson V
J Occup Med Toxicol; 2016; 11():37. PubMed ID: 27462362
[TBL] [Abstract][Full Text] [Related]
12. Malignant pleural mesothelioma: Treatment patterns and outcomes from the Spanish Lung Cancer Group.
Remon J; Nadal E; Dómine M; Ruffinelli J; García Y; Pardo JC; López R; Cilleruelo A; García-Campelo R; Martín P; Juan O; González-Larriba JL; Provencio M; Olmedo E; Ponce S; Cumplido D; Barenys C; Majem M; Massutti B; Rodriguez-Abreu D; Porta R; Sala MA; Martinez-Kareaga M; Lianes P; Reguart N
Lung Cancer; 2020 Sep; 147():83-90. PubMed ID: 32682189
[TBL] [Abstract][Full Text] [Related]
13. Current therapies for malignant pleural mesothelioma.
Nakano T
Environ Health Prev Med; 2008 Mar; 13(2):75-83. PubMed ID: 19568885
[TBL] [Abstract][Full Text] [Related]
14. Mesothelioma risk associated with asbestos production in Slovenia.
Vudrag M; Rihtar TK; Vegnuti M
Arh Hig Rada Toksikol; 2010 Mar; 61(1):45-52. PubMed ID: 20338867
[TBL] [Abstract][Full Text] [Related]
15. Malignant pleural mesothelioma incidence and survival in the Republic of Ireland 1994-2009.
Jennings CJ; Walsh PM; Deady S; Harvey BJ; Thomas W
Cancer Epidemiol; 2014 Feb; 38(1):35-41. PubMed ID: 24394956
[TBL] [Abstract][Full Text] [Related]
16. First-line chemotherapy with pemetrexed plus cisplatin for malignant peritoneal mesothelioma.
Fujimoto E; Kijima T; Kuribayashi K; Negi Y; Kanemura S; Mikami K; Doi H; Kitajima K; Nakano T
Expert Rev Anticancer Ther; 2017 Sep; 17(9):865-872. PubMed ID: 28594258
[TBL] [Abstract][Full Text] [Related]
17. Systemic treatments for mesothelioma: standard and novel.
Kindler HL
Curr Treat Options Oncol; 2008 Jun; 9(2-3):171-9. PubMed ID: 18770046
[TBL] [Abstract][Full Text] [Related]
18. Second-line chemotherapy in malignant pleural mesothelioma: results of a retrospective multicenter survey.
Zucali PA; Simonelli M; Michetti G; Tiseo M; Ceresoli GL; Collovà E; Follador A; Lo Dico M; Moretti A; De Vincenzo F; Lorenzi E; Perrino M; Giordano L; Farina G; Santoro A; Garassino M
Lung Cancer; 2012 Mar; 75(3):360-7. PubMed ID: 21937142
[TBL] [Abstract][Full Text] [Related]
19. Neoadjuvant chemotherapy and extrapleural pneumonectomy of malignant pleural mesothelioma with or without hemithoracic radiotherapy (SAKK 17/04): a randomised, international, multicentre phase 2 trial.
Stahel RA; Riesterer O; Xyrafas A; Opitz I; Beyeler M; Ochsenbein A; Früh M; Cathomas R; Nackaerts K; Peters S; Mamot C; Zippelius A; Mordasini C; Caspar CB; Eckhardt K; Schmid RA; Aebersold DM; Gautschi O; Nagel W; Töpfer M; Krayenbuehl J; Ribi K; Ciernik IF; Weder W
Lancet Oncol; 2015 Dec; 16(16):1651-8. PubMed ID: 26538423
[TBL] [Abstract][Full Text] [Related]
20. Multicentric study on malignant pleural mesothelioma in Turkey: clinicopathologic and survival characteristics of 282 patients.
Elkiran ET; Kaplan MA; Sevinc A; Aksoy S; Demirci U; Seker M; Harputluoglu H; Ozdemir NY; Isik F; Ulas A; Inanc M; Arslan UY; Dogu GG; Isikdogan A; Buyukberber S;
Med Oncol; 2012 Dec; 29(5):3147-54. PubMed ID: 22722923
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
